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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
probiotic supplementation is effective in reducing the incidence of atopic dermatitis in 
children age 3 and younger. 
 
STUDY DESIGN: Systematic review of three Engligh language primary studies one 
published in 2009 and the other two in 2010. 
 
DATA SOURCES: Three double blind randomized controlled trials comparing the 
efficacy of probiotic supplementation for reducing the incidence of atopic dermatitis in 
children ages 3 and under were found using Cochrane Library EBM and PubMed 
databases. 
 
OUTCOMES MEASURED:  Diagnosis of atopic dermatitis, via a positive skin-prick-test 
result or elevated specific immunoglobulin E [IgE] level , Atopic dermatitis severity using   
SCORAD scores pre/post intervention , and parental reported weekly diaries of the health status subjects, a British Medical Research Council questionnaire and the Dutch European community Respiratory Health Survey.  
 
RESULTS:  Minimal intervention-related adverse events were reported in the studies, and  
included feeding problems, formula intolerance, and the need for corticosteroid treatment. 
Niers et al showed in the first 3 months, parental reported incidence of atopic dermatitis 
was  significantly lower in the probiotic group 6/50 compared to the placebo group15/52, 
and p=0.035. Gruber et al demonstrated after 1 year, atopic dermatitis occurred in fewer 
infants from the probiotic group, (5.7%) than from the control group (9.7%), p=0.04 and CI is 95% and is narrow. Dotterud et al demonstrated at 2 years of age, probiotic 
intervention group showed 29/138  subjects were assessed as having atopic dermatitis( 
21%.) In the placebo group 48/140 were assessed as having atopic dermatitis (34.3%). The 
Odds ratio of the cumulative incidence of atopic dermatitis was calculated to be 0.51 and 
the p value was equal to 0.013.  The p value calculated determined that the incidence of 
atopic dermatitis in the probiotc group versus the placebo group was statistically 
significant (p<0.05).  
 
CONCLUSION: All three studies showed that  probiotic supplementation is effective in 
reducing the incidence of atopic dermatitis in children age 3 and under.  
 
KEY WORDS: atopic dermatitis, probiotics, pregnancy, children, infant atopic dermatitis 
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INTRODUCTION 
 
Atopic dermatitis is a chronic, inflammatory skin condition with prevalence rising 
in many industrialized countries. 5 Symptoms include erythema, scaling and pruritus in 
affected areas, and often result in sleeplessness, psychological stress, poor self-esteem, 
anxiety, and poor school or work performance.2  This paper evaluates three double blind 
randomized controlled trials comparing the efficacy of probiotic supplementation for 
reducing the incidence of atopic dermatitis in children ages 3 and under.   
Atopic dermatitis is the most common inflammatory skin disease in infancy. 
Unfortunately, incidence has increased steadily in the industrialized countries over the last 
3 decades and affects 10% to 20% of children.2  The disease often presents in early 
childhood and persists into adult life in 60% of patients.3   In the U.S. cost of atopic 
dermatitis treatment is estimated to be 0.9 to 3.8 billion dollars every year, with direct 
medical costs and out-of-pocket expenses averaging $609/patient/year.2  Atopic dermatitis 
is responsible for countless medical office visits.2 Atopic dermatitis adds to childhood 
morbidity and prevalence of allergic disease has increased in the past few decades. 5  
Hygiene hypothesis suggests increased prevalence is associated with reduced exposure to 
microbial components early in life.6   
Current treatment of atopic dermatitis includes skin hydration, emollients, 
avoidance of allergens and irritants, and use of antihistamine drugs or corticosteroids 
during exacerbations.5  The peak incidence of atopic dermatitis is in the first year of life. 5 
Positive family history is the strongest predictor for the development of atopic dermatitis, 
but  majority of children who express atopic disease have a negative family history.5 
Allergic disease has been associated with altered intestinal micro biota, 4 which plays an 
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important physiological role in the postnatal development of the immune system.5 
Probiotics have been suggested as a potential treatment for atopic dermatitis and may be a 
potential approach for prevention of this hard to treat skin condition.. 6 
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not 
probiotic supplementation is effective in reducing the incidence of atopic dermatitis in 
children age 3 and younger. 
METHODS 
 A number of criteria were considered in the selection of utilized studies.  Only 
double blind randomized  controlled trials that introduced  probiotic supplementation 
compared to placebo were considered. The population was limited to children under 3 
years of age. The following probiotic interventions were deemed acceptable: Lactobacillus 
rhamnosus , Lactobacillus acidophilus, La-5, Bifidobacterium animalis subsp lactis Bb-
12, nonhydrolyzed cow’s milk with short and long chain oliqosaccharides (ratio 9:1, 85% 
of mixture) and pectin derived acidic oliqosaccharides (15% of mixture), Bifidobacterium 
bifidium, Bifidobacterium lactis, and Lactococcus lactis.  Outcomes of interest included,  
positive  skin prick test results for elevated specific immunoglobulin E for atopic 
dermatitis , SCORAD scores, weekly parent diaries documenting atopy related symptoms 
and doctor visits .  SCORAD is a clinical tool used to assess the extent and severity of 
atopic dermatitis (SCORing Atopic Dermatitis) prior to and post treatment to determine 
effectiveness.  
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A detailed search was performed by the author of this review between January of 2012 
and February of the same year.   The online search  was completed using Cochrane 
Library EBM Database and PubMed Online  with the key words “atopic dermatitis, “  
“probiotics, “ “pregnancy,” “children,” and “infant atopic dermatitis.”   All three articles 
that were selected to be included in this review were written in the English language and 
published  in peer-reviewed journals from 2009 until present. A Cochrane Meta Analysis 
titled “Probiotics for treating eczema” was performed in 2008 but was not included in this 
meta-analysis and all articles used were published after 2008.  An additional meta-analysis 
titled  “Meta analysis of lactic acid bacteria as probiotics for the primary prevention of 
infantile eczema” was published by Zhu DL and Yang, W, H. in 2010 on PubMed.  No 
information from this meta-analysis will be used as part of this paper. Selection of studies 
was  based on relevance to the topic of interest and only  studies that reported patient 
oriented outcome (Patietn Oriented Evidence that Matters, or POEMS) were included.  
Inclusion criteria for all chosen literature included studies focusing on children up to the 
age of  3.  Exclusion criteria included children over the age of 3 , children whose mothers 
took antibiotics during breast feeding or in the first 2 weeks of the child’s life, mothers 
who had been taking probiotic supplements during the last 4 weeks, mothers who were 
Hepatitis B, HIV , and Group B strep positive during pregnancy, children with feeding 
problems or difficulty ingesting the study product, and infants with known congenital 
disease that could interfere with the study. The studies either reported p values or 
contained dichotomous data, which could be used to calculate Relative Risk 
Reduction/Increase (RRR/RRI), Absolute Risk Reduction/Increase (ARR/ARI) and 
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Numbers Needed to Treat/Harm (NNT/NNH).  Demographics of the three final selection 
are reported and displayed in Table 1. 
TABLE 1: Demographics & Characteristics of included studies 
STUDY TYPE  # 
PTS. 
AGE INCLUSION  
CRITERIA 
EXCLUSION 
CRITERIA 
W/
D 
INTERVENTIONS 
Dotterud 1 
(2010) 
Randomized 
double-
blind, 
placebo-
controlled 
study 
278 Up to 
2 years 
of age 
278 infants (138 mothers on 
probiotics, 140 mother’s on 
placebo) pregnant women who 
were planning to breastfeed 
during the first 3 postnatal 
months, were in week<36 of 
pregnancy, liked and tolerated 
fermented milk and were not at 
risk of developing pregnancy 
complications such as pre-
eclampsia. 
   Women who 
had been taking 
probiotic 
supplements 
during the last 4 
weeks or were 
planning to move 
away from study 
location. 
 
65 Women were given 250 mL 
of probiotic milk or placebo 
milk per day from 36 weeks' 
gestation to 3 months after 
delivery while 
breastfeeding. The probiotic 
milk contained 
Lactobacillus rhamnosus, 
Lactobacillus acidophilus 
La-5, and Bifidobacterium 
animalis subsp lactis Bb-12 
Gruber5 
(2010) 
Double 
blind, 
randomized 
placebo 
controlled 
study 
1130 Up to 
1 year 
of age 
Term weaned infants younger 
than 8 weeks without a family 
history of atopic dermatitis 
from northern Europe. Healthy 
term infants (gestational age 
37-42 weeks) with a normal 
birth weight (>10th percentile 
and <90th percentile for 
gestational age, age up to 8 
weeks when entering the study, 
without a positive history of 
allergic disease of a 
parent/sibling and without 
metabolic disorder requiring 
special diet. 
Mother with 
hepatitis B, HIV, 
group B strep 
during pregnancy; 
moms taking 
ABX during 
breast-feeding; 
infants with 
known congenital 
disease that could 
interfere with the 
study;  
 
129 Infants in the probiotics 
group received a 
nonhydrolyzed cow’s milk– 
based formula with a 
specific mixture of short- 
and long-chain oligo- 
saccharides (ratio 9:1, 85% 
of mixture) and pectin- 
derived acidic 
oligosaccharides (15% of 
mixture). The PG and CG 
received a starter formula 
for the first 6 months of life, 
and then a follow-on 
formula was offered.  
Niers 6 
(2009) 
Double 
blind, 
randomized 
placebo 
controlled 
study 
156 Up to 
24 
months 
156 pregnant women with a 
positive family history of 
allergic disease and their 
offspring 
Women recruited at least 2 
months before delivery 
 
Children were 
excluded if their 
mother received 
ABX treatment in 
the first 2 weeks 
of life, if ingestion 
of the study 
product was 
difficult because 
of vomiting or 
feeding problems 
for longer than 3 
weeks from birth, 
or any medical 
problems. 
 
54 Prenatal administration of a 
mixture of probiotic bacteria 
(Bifidobacterium bifidum, 
Bifidobacterium lactis, and 
Lactococcus lactis) to 
mothers of high-risk 
children and postnatal 
supplementation to their 
offspring for the first 12 
months of life. 
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OUTCOMES 
 The outcomes measure were those of patient oriented evidence that matters 
(POEMS), which includes incidence of atopic dermatitis. Niers, et al. measured  pre- and 
postnatal supplementation of probiotic bacteria and its prevention of atopic dermatitis  in high risk children for the first 24 months of life. 3  The study measured the outcomes by a variety of methods including parental reported weekly diaries of the health status of their child, any doctor visits, symptoms and complaints of eczema.3   A British Medical Research Council questionnaire  and the Dutch European community Respiratory Health Survey  was distributed to parents in the study to evaluate participants for symptoms at the age of 3, 12, and 24 months.3 Study subjects received a physical examination  and evaluation by a study blinded physician at ages 3, 12, and 24 months. 3 Parental reported eczema and physician diagnosed eczema was defined as noninfectious dermatitis with typical features such as redness, dryness, edema, oozing, itching, scratching and distribution.3  Dotterud, et al. measured if infants whose mothers ingested probiotic milk before birth and during breastfeeding were able to prevent allergic disease in the first 2 years of life compared to  infants whose mother’s ingested placebo milk.1  In order to measure the outcome, at 2 years of age,  all children were assessed for diagnosis of atopic dermatitis, via a positive skin-prick-test result for elevated specific immunoglobulin E [IgE] level.1   Gruber, et al.  addressed if supplementation  of prebiotics and immunoactive oligosaccharides prevent the development of atopic dermatitis in infants through the first year of life.2  Outcomes were measured  through Atopic dermatitis being diagnosed according to  standard criteria based on the typical 
                                                                    McLaughlin, Probiotics And Atopic Dermatitis    7 morphology and distribution of skin lesions, pruritus, and chronicity with a duration of at least 14 days and or chronically relapsing.2  SCORAD scores. T-helper 2–specific thymus and activation- regulated chemokine levels, total immunoglobulin E levels, and percentage sensitized to hen’s egg or cow’s milk.2 
RESULTS 
 Three double blind randomized controlled trials are analyzed in this review.  All 
participants observed for incidence of atopic dermatitis are 3 years of age or younger and 
were  introduced to probiotic treatment either directly through formula or prenatally 
through ingestion by their mothers.  All studies used  blinded participants receiving  
probiotic supplementation and were measured against a blinded placebo control  group.  
Results of all three studies supported supplementation with probiotics as an effective 
means to  prevent atopic dermatitis in children under the age of 3.  The results were 
presented in dichotomous form in the Gruber, et al.2 and Dotterud, et al.1 and the Niers, et 
al. study3. 
 The Dotterud, et al.  study assessed if probiotics given to pregnant women in a nonselected population could prevent atopic dermatitis  during the child’s first 2 years of life.1  Women received probiotic milk containing Lactobacillus rhamnosus GG, 
L. acidophilus La-5 and Bifidobacterium animalis subsp. Bb-12 or placebo milk from 36 
weeks gestation to 3 months postnatally during breastfeeding.1   At 2 years of age, 138 
children in the probiotic group and 140 chidren in the placebo group of  the study were 
assessed for  atopic dermatitis. Of those children in the probiotic group, 29 subjects of the 
138 were assessed as having atopic dermatitis for a total of 21%. (See Table 2)  Of those 
children in the placebo  group, 48 subjects of the 140 were assessed as having atopic 
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dermatitis for a total of 34.3%. (see Table 2)  The Odds ratio of the cumulative incidence 
of atopic dermatitis was calculated to be 0.51 and the p value was equal to 0.013.  The p 
value calculated determined that the incidence of atopic dermatitis in the priobitc group 
versus the placebo group was statistically significant (p<0.05).  TABLE 2: Cumulative incidence of atopic dermatitis among 2 year old children in the probiotic group and placebo group reported by Dotterud, et al. 
The control event rate (CER) was determined as those children  at 2 years of age dignosed with atopic dermatitis who were not receiving probiotic supplementation. The CER was calculated to be 34.3%.  The experimental event rate (EER) was determined as the number of children  at 2 years of age who had diagnosed atopic dermatitis and were receiving probiotic supplementation.  The EER was found to be 21%.  From this data, the relative risk reduction (RRR) was calculated to be 0.133 with a number needed to treat(NNT) of 8 Therefore for  every 8 children  who were treated with  probiotics there was one fewer incidence of atopic dermatitis  in the control group of children not taking probiotics.1     The Gruber, et al. study assessed if supplementation  of prebiotics and immunoactive oligosaccharides in infants reduces the incidence of atopic dermatitis in the first year of life.2    Healthy term infants from 5 European countires with low risk of 
atopic dermatitis were randomized to a prebiotic group and a control group.  A total of 414 
infants received a specific  mixture of neutral oligosaccharides and pectin-derived acetic 
# of participants in probiotic group, n 
# of participants in placebo group, n 
Probiotic group with AD Placebo group with AD % of Probiotic group with AD 
% of Placebo group with AD 
n=138 n=140 n=29 n=48 21% 34.3% 
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acid oligosaccharides probiotic formula while 416 infants received a placebo formula.  
Atopic dermatitis was diagnosed by a physician  according to standard criteria based on 
distribution of skin lesions, pruritus, and duration of at least 14 days or chronic relapse. 
Within the first year of life, atopic dermatitis occurred in stastically significant fewer 
infants from the prebiotic group, (5.7%) than from the control group (9.7%), p=0.04 and CI is 95%, lower value of 13 and upper value of 386 and is narrow2   (see Table 3)   The control event rate (CER) was determined as those children  at 1year of age dignosed with atopic dermatitis who were not receiving probiotic supplementation. The CER was calculated to be 9.7%.  The experimental event rate (EER) was determined as the number of children  at 1 year of age who had diagnosed atopic dermatitis and were receiving probiotic supplementation.  The EER was found to be 5.7%.  From this data, the relative risk reduction (RRR) was calculated to be 0.41 with a number needed to treat(NNT) of 25. The incidence of atopic dermatitis  was 
significantly lower by 44% in the prebiotic group versus the control group.  The number 
needed to treat to prevent 1 case of atopic dermatitis by supplementation of probiotics was 
25 infants. 
TABLE 3: Incidence of atopic dermatitis in probiotic infants VS. placebo in the first year 
of life reported by Gruber, et al.  # of infants, n  Incidence of  atopic dermatitis % of infants with atopic dermatits % of Probiotic group with AD probiotic group n=414 n=24 5.7% 21% placebo group n=416 n=40 9.7% 21% The Niers, et al. study assessed prenatal and postnatal supplementation of probiotic bacteria prevent allergic disease in high risk children in the first year of 
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Lactococcus lactis were prenatally administered to mothers of high-risk children and to 
their offspring for the first 12 months of life.  Originally 156 mothers were enrolled in the 
study but 54 of the participants met the exclusion criteria. (see Table 1) During the first 3 
months of the study, a total of 50 infants received the probiotic   mixture and 52 infants 
received the placebo mixture.  The number of infants in the placebo group fell to 48 
infants after 3 months and a total of 48 infants remained in the placebo group for 2 years. 
Dropout was due to motivational problems and the intervention group number remained at 
a constant 50 participants throughout the study.  In the first 3 months, parental reported 
incidence of atopic dermatitis was statistically significantly lower in the probiotic group 
6/50 compared to the placebo group15/52, and p=0.035. (see Table 4) Incidence of 
parental reported atopic dermatitis at year 1 was  23/50 for probiotic goup and 31/48  in 
the placebo group.  At 2 years, the incidence of atopic dermatitis rose to 27/50 in the 
probiotic group and 34/48 in the placebo group.  The number needed to treat was 5.9 at 
ages 3 and 12 months and increased to 6.7 at age 2 years. (see Table 5)   Table 4: Incidence of atopic dermatitis in the probiotic group and placebo group during the first w years of life as reported by Niers, et al. Time Infants with AD with probiotic intervention Infants with AD with placebo intervention 3months 6/50 (12%) 15/52 (28.8%) 1 year 23/50 (46%) 31/48 (64.6%) 2 years 27/50 (54%) 34/48 (71%)  Table 5: Efficacy of probiotics in prevention of Atopic Dermatitis (Dotterud et al, Gruber et al, Niers et al) 
Study  CER EER RRR RRR NNT P value CI 
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Because of the treatments analyzed in these studies, the safety of the patients involved was 
closely monitored throughout the trials. Since all three trials were measuring incidence of 
atopic dermatitis in a probiotic fed group versus a placebo fed group, the worst adverse 
event experienced was atopic dermatitis or intolerance to probiotic or placebo formula. 
Gruber, et al. reported 17 patients withdrew from the study due to formula intolerance and 
56 patients  received corticosteroid treatment for severe atopic dermatitis.2  Niers, et al. 
reported 2 participants withdrew from the study due to feeding problems.3   Dotterud, et al 
reported no adverse events during the study.1 (See Table 6) 
Table 6: Adverse Events Across Trials (# of patients monitored)  Dotterud et al( 278 ) Gruber et al(1130  ) Niers et al (156) Adverse Event    Feeding Problems   2 Formula Intolerance  17  Corticosteroids  56  
 
CONCLUSION 
The combination of probiotic bacteria used shows a preventative effect on the 
incidence of atopic dermatitis in high risk children, which seems to be sustained during the 
first 2 years of life.3   In analyzing the results, the preventative effect appears to be 
established within the first 3 months of life. 3 
 
Dotterud, et al. 34.3% 21% 38.7% 13.3% 8 p =0.013  CI:95%  Gruber, et al 9.7% 5.7% 41% 4% 25 p = 0.04 CI: 95% Niers ,et al 21% 6% -71% -15% -7 P=0.021 CI: 95% 
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